Financial Performance - The company's operating revenue for Q1 2024 was CNY 70,304,397.74, a decrease of 1.31% compared to the same period last year[3]. - The net profit attributable to shareholders was CNY -3,719,366.81, representing a decline of 126.13% year-over-year[3]. - Basic earnings per share were CNY -0.01, a decrease of 126.13% year-over-year[3]. - The company's gross profit margin decreased, with a gross profit of ¥30,750,596.80 in Q1 2024, down from ¥42,936,674.43 in Q1 2023[21]. - Net profit for Q1 2024 was a loss of ¥4,361,103.22, compared to a profit of ¥13,593,233.44 in Q1 2023[21]. - The company reported a comprehensive loss of ¥12,631,759.31 for Q1 2024, compared to a comprehensive income of ¥16,633,993.44 in Q1 2023[22]. Cash Flow - The net cash flow from operating activities was CNY -1,229,734.74, down 96.54% compared to the previous year[3]. - Cash flow from operating activities was ¥51,603,053.97, down from ¥62,861,217.44 in Q1 2023, indicating a decline in cash generation[24]. - The net cash flow from operating activities was -$1,229,734.74, a significant decrease from -$35,585,211.73 in the previous quarter[25]. - Total cash inflow from investment activities was $151,043,125.22, compared to $261,854,894.77 in the previous quarter, indicating a decline of approximately 42.4%[25]. - The net cash flow from investment activities was -$68,810,882.78, worsening from -$42,177,186.39 in the previous quarter[25]. - Cash inflow from financing activities totaled $20,000,000.00, while cash outflow was $30,434,991.67, resulting in a net cash flow of -$10,434,991.67[26]. - The ending cash and cash equivalents balance was $56,618,265.57, down from $78,666,223.80 in the previous quarter[26]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,645,165,559.81, a decrease of 0.76% from the end of the previous year[4]. - The company's cash and cash equivalents decreased to CNY 60,261,265.57 from CNY 140,736,190.61 at the end of 2023[16]. - The total liabilities decreased to ¥464,460,489.17 from ¥482,957,571.38 year-over-year[21]. - The company reported a total current liability of CNY 282,667,886.09, down from CNY 300,505,988.19 at the end of 2023[17]. Shareholder Information - The equity attributable to shareholders increased by 0.54% to CNY 1,223,533,561.83 compared to the end of the previous year[4]. - The total number of ordinary shareholders at the end of the reporting period was 34,263[8]. - The top ten shareholders held a total of 226,197,938 shares, accounting for 34.38% of the total shares[8]. - The total equity attributable to shareholders increased slightly to ¥1,223,533,561.83 from ¥1,216,978,966.74 in the previous year[21]. Expenses - The company recognized stock incentive expenses of CNY 14,295,625.00, which reduced net profit by CNY 11,518,012.50[4]. - The company recognized equity incentive expenses of CNY 14,295,625, resulting in a net profit reduction of CNY 11,518,012.50; excluding this impact, the net profit attributable to shareholders would be CNY 7,798,645.69[12]. - Total operating costs increased significantly to ¥79,483,781.34, up 30% from ¥61,195,825.19 in the same period last year[21]. - Research and development expenses were ¥5,495,990.24, a decrease of 16.8% from ¥6,604,724.12 in Q1 2023[21]. Other Financial Metrics - The weighted average return on equity was 0.30%, a decrease of 1.54 percentage points year-over-year[3]. - Accounts receivable rose to CNY 96,564,957.56 from CNY 84,947,031.64 at the end of 2023[16]. - Inventory decreased to CNY 93,045,354.79 from CNY 102,823,736.71 at the end of 2023[16]. - Short-term borrowings increased to CNY 70,000,000.00 from CNY 50,000,000.00 at the end of 2023[17]. - The impact of exchange rate changes on cash and cash equivalents was $684.15, contrasting with -$3,078.84 in the previous quarter[26].
海利生物(603718) - 2024 Q1 - 季度财报